ReviewActa pharmaceutica Sinica. B2021
Innate and adaptive immune responses toward nanomedicines.
Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Nanomaterials in gene therapy and genome editing: challenges and emerging directions.Journal of nanobiotechnology · 2025Review
- Mapping the research landscape of nanotechnology based immunotherapy for hepatocellular carcinoma.Discover oncology · 2025Article
- Glycerol-Based Polymer to Improve the Cellular Uptake of Liposomes.Biomacromolecules · 2025Article
- Doxorubicin-loaded PEGylated liposome modified with ANGPT2-specific peptide for integrative glioma-targeted imaging and therapy.Materials today. Bio · 2025Article
- Trypanosoma vivax elicits both Th1 and Th2 immunological responses in experimentally infected cattle.PloS one · 2025Article
- From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Advances and prospects of precision nanomedicine in personalized tumor theranostics.Frontiers in cell and developmental biology · 2024Review
- Lipid carriers for mRNA delivery.Acta pharmaceutica Sinica. B · 2023Review
- Advanced subunit vaccine delivery technologies: From vaccine cascade obstacles to design strategies.Acta pharmaceutica Sinica. B · 2023Review
- Immune-regulating camouflaged nanoplatforms: A promising strategy to improve cancer nano-immunotherapy.Bioactive materials · 2023Review
- Approved Nanomedicine against Diseases.Pharmaceutics · 2023Review
- miR-146a-5p Promotes the Inflammatory Response in PBMCs Induced by Microcystin-Leucine-Arginine.Journal of inflammation research · 2023Article
- Small molecule-based immunomodulators for cancer therapy.Acta pharmaceutica Sinica. B · 2022Review
- Superparamagnetic Iron Oxide Nanoparticles for Immunotherapy of Cancers through Macrophages and Magnetic Hyperthermia.Pharmaceutics · 2022Review
- Liposomes and liposome-like nanoparticles: From anti-fungal infection to the COVID-19 pandemic treatment.Asian journal of pharmaceutical sciences · 2022Review
- Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs.Acta pharmaceutica Sinica. B · 2022Review
- Contribution of Nanoscience Research in Antioxidants Delivery Used in Nutricosmetic Sector.Antioxidants (Basel, Switzerland) · 2022Review
- Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates.Frontiers in immunology · 2022Review
- Maternal COVID-19 Vaccination and Its Potential Impact on Fetal and Neonatal Development.Vaccines · 2021Review
- Nanovaccines against Animal Pathogens: The Latest Findings.Vaccines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the commercialization of the first liposomes used for drug delivery, Doxil/Caelyx® and Myocet®, tremendous progress has been made in understanding interactions between nanomedicines and biological systems. Fundamental work at the interface of engineering and medicine has allowed nanomedicines to deliver therapeutic small molecules and nucleic acids more efficiently. While nanomedicines are used in oncology for immunotherapy or to deliver combinations of cytotoxics, the clinical successes of gene silencing approaches like patisiran lipid complexes (Onpattro®) have paved the way for a variety of therapies beyond cancer. In parallel, the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has highlighted the potential of mRNA vaccines to develop immunization strategies at unprecedented speed. To rationally design therapeutic and vaccines, chemists, materials scientists, and drug delivery experts need to better understand how nanotechnologies interact with the immune system. This review presents a comprehensive overview of the innate and adaptative immune systems and emphasizes the intricate mechanisms through which nanomedicines interact with these biological functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.